Ritanserin, a 5-HT2 receptor antagonist, does not modify ECT-induced prolactin release.
The effect of pretreatment with ritanserin, a potent and selective serotonin-S2 (5-HT2) receptor antagonist, on the prolactin (PRL) response to electroconvulsive therapy (ECT) was studied in seven female patients suffering from major depressive disorder. They were given either ECT alone, or ECT after 10 or 20 mg ritanserin PO, and PRL was estimated in blood samples taken at times -5, 0, +5, +15, +30 and +60 min. The PRL responses after drug administration were not different from the responses after ECT alone. We conclude that, if serotonergic mechanisms are involved in the ECT-induced PRL increase, this neuroendocrine response seems to be rather a 5-HT1 than 5-HT2 receptor mediated event.
Papakostas
Y
Y
Athens University Medical School, Psychiatric Clinic, Eginition Hospital, Greece.
Markianos
M
M
Papadimitriou
G
G
Stefanis
C
C
D000368:Aged; D003866:Depressive Disorder / Q000628:therapy; D004565:Electroconvulsive Therapy / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010880:Piperidines / Q000494:pharmacology*; D011388:Prolactin / Q000097:blood*; D016713:Ritanserin; D012702:Serotonin Antagonists / Q000494:pharmacology*
D010880:Piperidines; D012702:Serotonin Antagonists; D016713:Ritanserin; D011388:Prolactin